Market Research Industry Reports

Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review, H1 2018, provides an overview of the Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 1 (NF1), also called von Recklinghausens disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausens Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 1 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Von Recklinghausens Disease) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type I (Von Recklinghausens Disease) - Overview
Neurofibromatoses Type I (Von Recklinghausens Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neurofibromatoses Type I (Von Recklinghausens Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurofibromatoses Type I (Von Recklinghausens Disease) - Companies Involved in Therapeutics Development
Array BioPharma Inc
AstraZeneca Plc
Pfizer Inc
SpringWorks Therapeutics LLC
Neurofibromatoses Type I (Von Recklinghausens Disease) - Drug Profiles
binimetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-0325901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurofibromatoses Type I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neurofibromatoses Type I (Von Recklinghausens Disease) - Dormant Projects
Neurofibromatoses Type I (Von Recklinghausens Disease) - Product Development Milestones
Featured News & Press Releases
Dec 10, 2012: Study Identifies Targeted Molecular Therapy For Untreatable NF1 Tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausens Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline by Array BioPharma Inc, H1 2018
Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline by AstraZeneca Plc, H1 2018
Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline by Pfizer Inc, H1 2018
Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline by SpringWorks Therapeutics LLC, H1 2018
Neurofibromatoses Type I (Von Recklinghausens Disease) - Dormant Projects, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausens Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H1 2018

Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I (Von Recklinghausens Disease) - Pipeline Review, H1

USD 2000View Report

Neurofibromatoses Type I (Von Recklinghausen’s Disease) Global Clinical Trials Review, H1, 2018

Neurofibromatoses Type I (Von Recklinghausens Disease) Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Neurofibromatoses Type I (Von Recklinghausens Disease) Global Clinical Trials Review, H1, 2018 provides an overview

USD 2500View Report

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2018

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2018, provides

USD 2000View Report

72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Pipeline Review, H2 2018

72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Pipeline Review, H2

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Jun 2018
No. of Pages :49
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube